MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination with Cemiplimab in Patients with Advanced Solid Tumors and Lymphomas.

Phase 1
Recruiting
Conditions
Lymphoma, Non-Hodgkin
Follicular Lymphoma
Bladder Cancer
Metastatic Cancer
Tumor Recurrence
Uveal Melanoma, Recurrent
Carcinoma in Situ
Skin Cancer
Tumor, Solid
Triple Negative Breast Cancer
Interventions
Drug: ONM-501
Drug: Cemiplimab
First Posted Date
2023-09-01
Last Posted Date
2024-11-27
Lead Sponsor
OncoNano Medicine, Inc.
Target Recruit Count
168
Registration Number
NCT06022029
Locations
🇦🇺

University of the Sunshine Coast Clinical Trials, Buderim, Queensland, Australia

🇦🇺

Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia

🇺🇸

California Research Institute, Los Angeles, California, United States

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath